Last reviewed · How we verify
A second dose with an 3 year interval
A second dose with an 3 year interval is a Biologic drug developed by Shanghai Municipal Center for Disease Control and Prevention. It is currently FDA-approved.
Ocrelizumab is a small molecule used to treat conditions such as Relapsing Multiple Sclerosis, Multiple Sclerosis, and Primary Progressive Multiple Sclerosis, as per ClinicalTrials.gov. The exact mechanism of action of ocrelizumab is not specified in the provided information, but it is listed as a small molecule on ChEMBL.
At a glance
| Generic name | A second dose with an 3 year interval |
|---|---|
| Sponsor | Shanghai Municipal Center for Disease Control and Prevention |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Early Signs of Efficacy of IL12-L19L19. (PHASE1)
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (PHASE3)
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (PHASE1)
- Korea Comirnaty Post-marketing Surveillance
- Optimizing the Treatment Strategy for Age-related Macular Degeneration (NA)
- Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors (NA)
- Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years (PHASE1)
- Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A second dose with an 3 year interval CI brief — competitive landscape report
- A second dose with an 3 year interval updates RSS · CI watch RSS
- Shanghai Municipal Center for Disease Control and Prevention portfolio CI
Frequently asked questions about A second dose with an 3 year interval
What is A second dose with an 3 year interval?
Who makes A second dose with an 3 year interval?
What development phase is A second dose with an 3 year interval in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing